Nita Patel

Last updated
Nita Patel
Born1965 (age 57–58)
Sojitra
Alma mater Johns Hopkins University
Sardar Patel University
Scientific career
Institutions Novavax
AstraZeneca

Nita K. Patel (born 1965) is an Indian-American vaccinologist who leads vaccine development at Novavax. She oversaw the development of the Novavax COVID-19 vaccine.

Contents

Early life and education

Patel was born in Sojitra, a farming village in Gujarat. When she was four years old her father contracted tuberculosis, and came close to death. [1] This experience motivated Patel to become a physician and attempt to find a cure for tuberculosis. [2] She went on to earn a master's degree in microbiology at Sardar Patel University and a master's degree in biotechnology at Johns Hopkins University.

Research and career

After graduating from Johns Hopkins, Patel moved to Gaithersburg, Maryland where she worked for MedImmune, a company that looked to create vaccinations for tuberculosis, respiratory syncytial virus and Lyme disease. [2] She was the sixteenth member of the MedImmune team. [3] Later the company eventually acquired by AstraZeneca. [3]

In 2015, Patel left AstraZeneca to join Novavax, a biotechnology start-up in Maryland. Her research considers antibody discovery and vaccine development. [4] She oversaw the development of the Novavax COVID-19 vaccine, and led an all-woman team. [4] [5] [6] [7] After Patel received the SARS-CoV-2 spike protein in February 2020, she designed and characterized over twenty variants of the protein. [3] This involved identifying the locations where antibodies bind to the protein, and developing tests to check whether the spike is consistent between manufacturing plant. [3] The vaccines developed by Patel and Novavax make use of recombinant DNA. [8] In an interview with Science Magazine, Patel said that she had worked eighteen hour days to develop the vaccine, but didn't get tired. [9] They were awarded a $1.6 billion contract to run clinical trials. [10] In 2021, the vaccine was shown to be 89% effective in large trials in the United Kingdom. [11] [12]

Selected publications

Personal life

Patel is married to an American biochemist. [1]

Related Research Articles

A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

<span class="mw-page-title-main">Sarah Gilbert</span> British vaccinologist

Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">Kizzmekia Corbett</span> American immunologist

Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is an Assistant Professor of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and the Shutzer Assistant Professor at the Harvard Radcliffe Institute since June 2021.

<span class="mw-page-title-main">Oxford–AstraZeneca COVID-19 vaccine</span> Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

<span class="mw-page-title-main">Novavax COVID-19 vaccine</span> Vaccine against COVID-19

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). Full results from Nuvaxovid's pivotal phase III trial were published in December 2021.

<span class="mw-page-title-main">ZF2001</span> Vaccine against COVID-19

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering the urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">SCB-2019</span> Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

<span class="mw-page-title-main">Sanofi–GSK COVID-19 vaccine</span> Vaccine candidate against COVID-19

The Sanofi–GSK COVID-19 vaccine sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.

<span class="mw-page-title-main">MVC COVID-19 vaccine</span> Vaccine against COVID-19

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.

<span class="mw-page-title-main">NDV-HXP-S</span> Vaccine candidate against COVID-19

NDV-HXP-S is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">COVID-19 vaccination in Japan</span> Plan to immunize against COVID-19 in Japan

COVID-19 vaccination in Japan started later than in most other major economies. The country has frequently been regarded as "slow" in its vaccination efforts.

<span class="mw-page-title-main">COVAX-19</span> Vaccine candidate against COVID-19

COVAX-19 is the result of a collaboration between Vaxine and CinnaGen, a private company with operations in the Middle East. COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span>

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

<span class="mw-page-title-main">S-268019</span> Vaccine candidate against COVID-19

S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.

References

  1. 1 2 "Nita Patel is leading the vaccine team of Novavax in US..." www.asian-voice.com. Retrieved 2021-04-06.
  2. 1 2 "Meet Nita Patel, An American-Indian Scientist Who is Breaking Ground in Vaccinology - SheThePeople TV" . Retrieved 2021-04-06.
  3. 1 2 3 4 Wadman, Meredith (2020-11-06). "'Nothing is impossible,' says lab ace Nita Patel". Science. 370 (6517): 652. Bibcode:2020Sci...370..652W. doi: 10.1126/science.370.6517.652 . ISSN   0036-8075. PMID   33154121.
  4. 1 2 O'Donnell, Norah (April 1, 2021). "Meet the women at forefront of COVID-19 vaccine development". www.cbsnews.com. Retrieved 2021-04-06.
  5. ↑ "View: Why are all the prominent Covid vaccines developed by women?". The Economic Times. Retrieved 2021-04-06.
  6. ↑ Tu, Jessie (2020-03-10). "Meet some of the women trying to beat the spread of coronavirus". Women's Agenda. Retrieved 2021-04-06.
  7. ↑ "Women and the Vaccine". Millennial Matriarchs. 2020-04-28. Retrieved 2021-04-06.
  8. ↑ Bhattacharya, Shriya. "Meet Dr. Nita Patel and her All-Female Team Developing the COVID-19 Vaccine". Brown Girl Magazine. Retrieved 2021-04-06.
  9. ↑ Cantwell, Meagan (2020-11-17). "This scientist buoys a small firm's quest to make a top-notch COVID-19 vaccine". Science | AAAS. Retrieved 2021-04-06.
  10. ↑ "Novavax $1.6B vaccine contract: Is this the start of something big?". baltimoresun.com. Retrieved 2021-04-06.
  11. ↑ "Covid-19: Novavax vaccine shows 89% efficacy in UK trials". BBC News. 2021-01-29. Retrieved 2021-04-06.
  12. ↑ "Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial". CNBC. 2021-03-11. Retrieved 2021-04-06.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.